- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03319264
Sarcopenia in Axial and Peripheral Spondyloarthropathies (SASPAR)
Spondylarthropathies (SpA) are among the most common chronic inflammatory rheumatisms in adults, responsible for a muscular loss or sarcopenia which can be very disabling, not much documented in the literature, and not yet studied in France. In addition, sarcopenia is associated with decreased physical activity and increased risk of falls and fractures. A better characterization of the determinants of this muscular loss will allow to better detect and take care of it.
The aim is to conduct the first French study on the prevalence and severity of sarcopenia in patients with spondyloarthropathies and to study the variables that may be associated with it. Finally, we propose to evaluate obesity related to sarcopenia in these patients and compare them to cases matched for age and sex (from OFELY / STRAMBO cohorts, Lyon, FRANCE).
This is a prospective interventional and monocentric study with minimal risks and constraints: patients will be included for one day for an evaluation of their sarcopenia by measuring their muscle strength, physical performance and body composition and recording of their socio-demographic and disease characteristics.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69003
- Service de Rhumatologie - Hôpital Edouard Herriot
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, 18 to 80 years old
- Hospitalized or attending the rheumatology department for spondyloarthopathy.
Exclusion Criteria:
- no signed consent
- Immobilization for a period of more than 15 days during the last 3 months
- pregnant or breastfeeding woman
- Not affiliated to the national healthcare insurance
- difficulty in understanding French
- psychiatric disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with SpA
Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :
|
Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
A 4 metres walking test will be performed to assess patient's walking speed
DXA measurement will be performed to assess patient's body composition
Patient's quality of life will be assessed thanks to the SARQOL questionnaire
Life habits Questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscular strength
Time Frame: At day 1
|
Muscular strength is the first outcome to evaluate sarcopenia
|
At day 1
|
Walking speed
Time Frame: At day 1
|
Walking speed is a physical performance outcome, that is the second outcome to evaluate sarcopenia
|
At day 1
|
Muscular mass
Time Frame: Up to 4 month after inclusion
|
Muscular mass is the third outcome to evaluate sarcopenia and will be assessed using DXA
|
Up to 4 month after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol consumption
Time Frame: At day 1
|
At day 1
|
|
Tobacco consumption
Time Frame: At day 1
|
At day 1
|
|
Time of sport practice per month
Time Frame: At day 1
|
Number of hours of sport practice per month is the first outcome to evaluate patient's global physical activity.
|
At day 1
|
Physical activity rate in work
Time Frame: At day 1
|
Physical activity rate in work can be light, medium, high or not applicable if the patient does not work ; it is the second outcome to evaluate patient's physical global activity.
|
At day 1
|
Average walking time in a week
Time Frame: At day 1
|
Average walking time in a week is the third outcome to evaluate patient's physical global activity.
|
At day 1
|
Score at the SARQOL questionnaire
Time Frame: At day 1
|
Quality of life will be assessed thanks to the SARQOL questionnaire (score between 0 and 100)
|
At day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Infections
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Spinal Diseases
- Bone Diseases
- Muscular Atrophy
- Atrophy
- Bone Diseases, Infectious
- Sarcopenia
- Spondylitis
- Spondylarthritis
- Spondylarthropathies
Other Study ID Numbers
- 69HCL17_0145
- 2017-A02391-52 (Other Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on Dynamometry exam
-
Clinical Exercise Physiology and Rehabilitation...Not yet recruitingRotator Cuff Tear or Rupture, Not Specified as Traumatic | Rotator Cuff Tears | Rotator Cuff Tendinosis | Rotator Cuff Syndrome | Rotator Cuff Impingement
-
Spinal Cord Injury Centre of Western DenmarkUniversity of AarhusUnknown
-
Assistance Publique - Hôpitaux de ParisCompletedRespiration | Ventilator Weaning | Hand StrengthFrance
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedMuscle Weakness | Muscle StrengthBrazil
-
Karolinska University HospitalCompleted
-
University of CincinnatiActive, not recruiting
-
Radboud University Medical CenterSolve FSHDRecruitingMuscular Dystrophy, FacioscapulohumeralNetherlands
-
The University of Texas Health Science Center,...Completed